AU2018239352A1 - NPRA agonists, compositions, and uses thereof - Google Patents

NPRA agonists, compositions, and uses thereof Download PDF

Info

Publication number
AU2018239352A1
AU2018239352A1 AU2018239352A AU2018239352A AU2018239352A1 AU 2018239352 A1 AU2018239352 A1 AU 2018239352A1 AU 2018239352 A AU2018239352 A AU 2018239352A AU 2018239352 A AU2018239352 A AU 2018239352A AU 2018239352 A1 AU2018239352 A1 AU 2018239352A1
Authority
AU
Australia
Prior art keywords
sequence
peptide
natriuretic peptide
cgmp
anp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018239352A
Other languages
English (en)
Inventor
Elijah Bolotin
Gerardo M. Castillo
Akiko Nishimoto-Ashfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmain Corp
Original Assignee
Pharmain Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Corp filed Critical Pharmain Corp
Publication of AU2018239352A1 publication Critical patent/AU2018239352A1/en
Priority to AU2025201270A priority Critical patent/AU2025201270A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018239352A 2017-03-22 2018-03-21 NPRA agonists, compositions, and uses thereof Abandoned AU2018239352A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201270A AU2025201270A1 (en) 2017-03-22 2025-02-21 NPRA agonists, compositions, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475147P 2017-03-22 2017-03-22
US62/475,147 2017-03-22
PCT/US2018/023491 WO2018175534A1 (en) 2017-03-22 2018-03-21 Npra agonists, compositions, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201270A Division AU2025201270A1 (en) 2017-03-22 2025-02-21 NPRA agonists, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
AU2018239352A1 true AU2018239352A1 (en) 2019-10-10

Family

ID=63585777

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018239352A Abandoned AU2018239352A1 (en) 2017-03-22 2018-03-21 NPRA agonists, compositions, and uses thereof
AU2025201270A Pending AU2025201270A1 (en) 2017-03-22 2025-02-21 NPRA agonists, compositions, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201270A Pending AU2025201270A1 (en) 2017-03-22 2025-02-21 NPRA agonists, compositions, and uses thereof

Country Status (15)

Country Link
US (1) US20200017567A1 (https=)
EP (1) EP3601314A4 (https=)
JP (2) JP7126270B2 (https=)
KR (1) KR102714599B1 (https=)
CN (1) CN110603260B (https=)
AU (2) AU2018239352A1 (https=)
BR (1) BR112019019720A2 (https=)
CA (1) CA3056433A1 (https=)
EA (1) EA201992226A1 (https=)
IL (1) IL269388B2 (https=)
MX (1) MX2019010960A (https=)
MY (1) MY201165A (https=)
PH (1) PH12019550163A1 (https=)
SG (1) SG11201908580XA (https=)
WO (1) WO2018175534A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236688A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
EP3972589B1 (en) * 2019-05-22 2024-07-03 Merck Sharp & Dohme LLC Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
US20230241164A1 (en) * 2020-06-12 2023-08-03 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer
IL298980A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and methods thereof in treating acute lung injury
IL320341A (en) * 2022-10-21 2025-06-01 Lilly Co Eli Long-acting natriuretic peptides and uses thereof
EP4612167A1 (en) * 2022-11-02 2025-09-10 Novo Nordisk A/S Cnp compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985722A (en) * 1973-12-12 1976-10-12 Ajinomoto Co., Inc. Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins
FR2687156B1 (fr) * 1992-02-12 1994-04-01 Roussel Uclaf Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives.
CN1062311C (zh) * 1996-12-27 2001-02-21 中国医学科学院基础医学研究所 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
JP4237375B2 (ja) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
AU2003297583B2 (en) * 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
EP2162464A1 (en) * 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
CN101809029B (zh) * 2008-05-23 2016-06-15 第一三共株式会社 具有延长目标肽的血浆半衰期作用的肽
ES2608457T3 (es) * 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CN103402534B (zh) * 2011-02-23 2016-10-12 麦德林制药私人有限公司 用于治疗充血性心力衰竭的治疗方法
EP2678028A2 (en) * 2011-02-25 2014-01-01 Medtronic, Inc. Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides

Also Published As

Publication number Publication date
IL269388B1 (en) 2024-11-01
EP3601314A1 (en) 2020-02-05
MX2019010960A (es) 2020-01-20
EA201992226A1 (ru) 2020-02-12
JP2022090049A (ja) 2022-06-16
CN110603260B (zh) 2023-11-07
EP3601314A4 (en) 2021-01-13
KR20190133201A (ko) 2019-12-02
CN110603260A (zh) 2019-12-20
SG11201908580XA (en) 2019-10-30
JP7126270B2 (ja) 2022-08-26
WO2018175534A1 (en) 2018-09-27
KR102714599B1 (ko) 2024-10-07
AU2025201270A1 (en) 2025-03-13
IL269388A (en) 2019-11-28
JP2020511494A (ja) 2020-04-16
MY201165A (en) 2024-02-08
PH12019550163A1 (en) 2020-06-08
US20200017567A1 (en) 2020-01-16
CA3056433A1 (en) 2018-09-27
BR112019019720A2 (pt) 2020-04-28
IL269388B2 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
AU2025201270A1 (en) NPRA agonists, compositions, and uses thereof
US12083164B2 (en) Amylin analogues
CA3136163A1 (en) Multi-receptor agonist and medical use thereof
AU2021254623B2 (en) Long-acting adrenomedullin derivative
JPH08504823A (ja) エンドセリン拮抗薬
KR20170020820A (ko) Tat-nr2b9c의 클로라이드 염
WO2021093883A1 (zh) 双受体重激动剂化合物及其药物组合物
EP2911686B1 (en) Peptides for preventing ischemic tissue injury
KR101909052B1 (ko) 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
EA044180B1 (ru) Агонисты npra, композиции и их использование
HK40017696B (zh) Npra激动剂、组合物及其用途
HK40017696A (en) Npra agonists, compositions, and uses thereof
HK40004264B (en) Amylin analogues

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted